1921
Volume 99, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Urinary schistosomiasis causes damage to the urological system. Ultrasound is a method that detects the burden of secondary disease, individually and in epidemiological studies. In this study, the –associated urinary tract pathology is analyzed before and after treatment in a short period of time. Seventy children who had previously participated in an epidemiological study on schistosomiasis in the city of Cubal, Angola, and had also performed urinary ultrasound between August 2013 and February 2014 were cited 6–8 months later to assess the possible reinfection and repeat new urinary ultrasound, analyzing changes at the level of urinary pathology. The presence of hematuria and proteinuria was also analyzed. Of the 70 children analyzed, 29 (41.4%) were girls, with an average age of 10.4 years (standard deviation 2.3). Fifty-three (75.7%) had an improvement in their bladder and/or kidney scores, whereas 12 (17.1%) had no change and five (7.1%) had progression of the disease. None of the parameters analyzed completely disappeared. After one single course of treatment with praziquantel, all the analyzed parameters showed regression. Improvement was greater in the urinary bladder than in the upper urinary tract, though these lesions also reversed; the reversion of all parameters was greater among children older than 10 years old than the younger ones. Proteinuria was the parameter with a smaller reduction. Ultrasound should be a usual tool for diagnosis and follow-up in urinary schistosomiasis, particularly in children; more accurate recommendations about follow-up in the case of children whose lesions do not reverse should be established.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0343
2018-08-20
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/4/tpmd180343.html?itemId=/content/journals/10.4269/ajtmh.18-0343&mimeType=html&fmt=ahah

References

  1. Chitsulo L, Engels D, Montresor A, Savioli L, , 2000. The global status of schistosomiasis and its control. Acta Trop 77: 4151. [Google Scholar]
  2. King CH, Dickman K, Tisch D, , 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability related outcomes in endemic schistosomiasis. Lancet 365: 15611569. [Google Scholar]
  3. Gryseels B, Polman K, Clerinx J, Kestens L, , 2006. Human schistosomiasis. Lancet 368: 11061118. [Google Scholar]
  4. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, , 2006. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6: 411425. [Google Scholar]
  5. Murray CJ, 2013. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380: 21972223. [Google Scholar]
  6. World Health Organization, 1985. The control of schistosomiasis: report of a WHO Expert Committee. World Health Organ Tech Rep Ser 728: 1113. [Google Scholar]
  7. WHO, 2002. Prevention and Control of schistosomiasis and Soil-Transmitted helminthiasis: Report of a WHO Expert Committee. Report No.: 912. Technical Report Series. Geneva, Switzerland: World Health Organization.
  8. WHO, 2006. Preventive Chemotherapy in Human helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
  9. Hatz CF, , 2001. The use of ultrasound in schistosomiasis. Adv Parasitol 48: 225284. [Google Scholar]
  10. Akpata R, Neumayr A, Holtfreter MC, Krantz I, Singh DD, Mota R, Walter S, Hatz C, Richter J, , 2015. The WHO ultrasonography protocol for assessing morbidity due to Schistosoma haematobium. Acceptance and evolution over 14 years. Systematic review. Parasitol Res 114: 12791289. [Google Scholar]
  11. Brouwer KC, Ndhlovu PD, Wagatsuma Y, Munatsi A, Shiff CJ, , 2003. Epidemiological assessment of Schistosoma haematobium-induced kidney and bladder pathology in rural Zimbabwe. Acta Trop 85: 339347. [Google Scholar]
  12. Kahama AI, Vennervald BJ, Kombe Y, Kihara RW, Ndzovu M, Mungai P, Ouma JH, , 1999. Parameters associated with Schistosoma haematobium infection before and after chemotherapy in school children from two villages in the coast province of Kenya. Trop Med Int Health 4: 335340. [Google Scholar]
  13. Andrade G, Bertsch DJ, Gazzinelli A, King CH, , 2017. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis 11: e0005372. [Google Scholar]
  14. Shen Y, 2017. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries. BMC Infect Dis 17: 652. [Google Scholar]
  15. Doehring E, Ehrich JH, Bremer HJ, , 1986. Reversibility of urinary tract abnormalities due to Schistosoma haematobium infection. Kidney Int 30: 582585. [Google Scholar]
  16. Bocanegra C, 2015. Epidemiology of schistosomiasis and usefulness of indirect diagnostic tests in school-age children in Cubal, central Angola. PLoS Negl Trop Dis 9: e0004055. [Google Scholar]
  17. Bocanegra García C, 2018. Ultrasound findings and associated factors to morbidity in Schistosoma haematobium infection in a highly endemic setting. Trop Med Int Health 23: 221228. [Google Scholar]
  18. Richter J, Hatz C, Campagne G, Bergquist N, Jenkins J, , 2000. Ultrasound in schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of schistosomiasis-Related Morbidity. Geneva, Switzerland: World Health Organization.
  19. Magak P, Chang-Cojulun A, Kadzo H, Ireri E, Muchiri E, Kitron U, King CH, , 2015. Case-control study of posttreatment regression of urinary tract morbidity among adults in Schistosoma haematobium-endemic communities in Kwale County, Kenya. Am J Trop Med Hyg 93: 371376. [Google Scholar]
  20. DeAlegria MLAR, 2017. Prevalence of Strongyloides stercoralis and other intestinal parasite infections in school children in a rural area of Angola: a cross-sectional study. Am J Trop Med Hyg 97: 12261231. [Google Scholar]
  21. Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, Gärtner F, Correia da Costa JM, , 2017. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 61: pii:e0258216. [Google Scholar]
  22. Senghor B, Diaw OT, Doucoure S, Seye M, Diallo A, Talla I, CT, Sokhna C, , 2016. Impact of annual praziquantel treatment on urogenital schistosomiasis in a seasonal transmission focus in central Senegal. PLoS Negl Trop Dis 10: e0004557. [Google Scholar]
  23. Zwang J, Olliaro PL, , 2014. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8: e3286. [Google Scholar]
  24. Nalugwa A, Nuwaha F, Tukahebwa EM, Olsen A, , 2015. Single versus double dose praziquantel comparison on efficacy and Schistosoma mansoni re-infection in preschool-age children in Uganda: a randomized controlled trial. PLoS Negl Trop Dis 9: e0003796. [Google Scholar]
  25. Garba A, 2013. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128: 334344. [Google Scholar]
  26. Ahmed AM, Abbas H, Mansour FA, Gasim GI, Adam I, , 2012. Schistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantel. Parasit Vectors 5: 108. [Google Scholar]
  27. Olliaro PL, 2011. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5: e1165. [Google Scholar]
  28. Russell Stothard J, Sousa-Figueiredo JC, Simba Khamis I, Garba A, Rollinson D, , 2009. Urinary schistosomiasis-associated morbidity in school children detected with urine albumin to creatinin ratio (UACR) reagent strips. J Pediatr Urol 5: 287291. [Google Scholar]
  29. Murare HM, Taylor P, , 1987. Haematuria and proteinuria during Schistosoma haematobium infection: relationship to intensity of infection and the value of chemical reagent strips for pre and post-treatment diagnosis. Trans R Soc Trop Med Hyg 81: 426430. [Google Scholar]
  30. Honeycutt J, Hammam O, Fu CL, Hsieh MH, , 2014. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol 30: 324332. [Google Scholar]
  31. Danso-Appiah A, Utzinger J, Liu J, Olliaro P, , 2008. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 200: CD000053. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0343
Loading
/content/journals/10.4269/ajtmh.18-0343
Loading

Data & Media loading...

  • Received : 21 Apr 2018
  • Accepted : 18 Jun 2018
  • Published online : 20 Aug 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error